URAC Specialty Pharmacy Accreditation Consulting — Integral Healthcare Solutions
IHS is a specialized healthcare accreditation consulting firm with over 25 years of URAC and NCQA expertise. We guide specialty pharmacies through every phase of URAC Specialty Pharmacy Accreditation v6.0 — from Standard-by-Standard Review through committee decision — whether you are an independent pharmacy, a hospital outpatient operation, or a health system building a specialty dispensing program from the ground up.
What Is URAC Specialty Pharmacy Accreditation?
URAC Specialty Pharmacy Accreditation is a three-year quality credential awarded by the Utilization Review Accreditation Commission (URAC) to specialty pharmacies that demonstrate compliance with rigorous standards across 9 operational modules: Risk Management (RM), Operations and Infrastructure (OPIN), Performance Monitoring and Improvement (PMI), Consumer Protection and Empowerment (CPE), Pharmacy Operations (P-OPS), Medication Distribution (P-MD), Patient Service and Communication (P-PSC), Patient Management (PM), and Reporting Performance Measures (RPT). The current standard is Specialty Pharmacy v6.0, announced October 2025, succeeding v5.0 which had been active since October 2022.
This accreditation is not optional for pharmacies that want to compete in the specialty drug market. With $265 billion in US specialty pharmaceutical dispensing revenue in 2024 and 75% of the roughly 7,000 drugs currently in clinical development classified as specialty medications, the market is massive and growing. But access to that market runs through accreditation — PBMs, manufacturers, and payers use it as a gatekeeper for network inclusion, limited distribution drug access, and contract eligibility.
Who Needs URAC Specialty Pharmacy Accreditation?
Six categories of organizations pursue URAC specialty pharmacy accreditation:
- Independent specialty pharmacies — the largest group by location count, though facing shrinking revenue share against PBM-affiliated chains. Accreditation is the minimum barrier to network participation.
- Hospital and health system outpatient pharmacies — the fastest-growing segment, expanding from 15% to 27% of all accredited specialty pharmacies between 2017 and 2024, driven by 340B Drug Pricing Program financial incentives.
- PBM-affiliated specialty pharmacies — CVS/Caremark, OptumRx, and Express Scripts operations that collectively capture 66% of all pharmacy-dispensed specialty drug revenues.
- Exclusive dispensing pharmacies — operations like PANTHERx Rare and Onco360 that handle rare disease and orphan drug limited distribution contracts where manufacturers mandate accreditation.
- Mail service pharmacies — organizations pursuing URAC Mail Service Pharmacy Accreditation alongside or instead of the specialty designation.
- Small independent pharmacies — eligible for URAC's dedicated Small Business Specialty Pharmacy Accreditation program with special affordable pricing.
Why Accreditation Is a Market Access Requirement
Accreditation is not a nice-to-have. It is a contractual prerequisite. PBMs use URAC accreditation as a gatekeeper for inclusion in limited distribution networks (LDNs). Drug manufacturers require it before granting exclusive dispensing contracts for high-cost specialty and orphan drugs. Approximately 66% of commercial payers prefer URAC accreditation specifically, making it the dominant standard in the specialty pharmacy market.
OptumRx contractually requires URAC, ACHC, or TJC accreditation for specialty pharmacy network participation. CVS Caremark and Express Scripts maintain similar credentialing thresholds. For independent pharmacies, losing accreditation means losing network access — and losing network access means losing the business.
North Carolina has gone further: Session Law 2025-69 (SB 203) now provides explicit statutory protection for URAC-accredited pharmacies against PBM-imposed redundant credentialing documentation requirements that exceed North Carolina Board of Pharmacy standards. URAC accreditation is becoming a legal shield, not just a quality signal.
The URAC Specialty Pharmacy Accreditation Process: Phase by Phase
URAC specialty pharmacy accreditation realistically takes 9 to 12 months from consulting engagement kickoff to final committee decision. URAC states the process takes six months or less from formal application submission, but that timeline assumes your pharmacy already has compliant policies, functioning patient management programs, and audit-ready documentation — which almost no organization has. Here is what the process looks like with IHS guiding each phase.
Phase 1: Standard-by-Standard Review (Months 1-2)
IHS conducts an educational Standard-by-Standard Review, training your staff on every applicable standard and explaining what URAC reviewers expect to see during the desktop review. This is not a checklist audit — it is a comprehensive educational engagement that builds your team's understanding of each standard's requirements. You receive a clear picture of exactly what documentation needs to be built, revised, or created — and how long each element will take.
Phase 2: Document Preparation (Months 2-5)
This is where most pharmacies underestimate the work. IHS provides policy templates for all applicable standard modules and assists your team with writing and customizing policies and procedures to your specific operations. We provide Patient Management program frameworks, Quality Management Committee charter templates, and clinical documentation templates — your team adapts these to your pharmacy's workflows and software systems. IHS does not interact with your dispensing software or conduct staff training directly; we equip your internal team with the compliance frameworks they need to build and sustain a compliant operation.
Phase 3: Application Submission via AccreditNet (Months 5-6)
The formal application defines your scope of services, organizational structure, and any delegation activities. IHS prepares and reviews your entire documentation package for upload to URAC's AccreditNet platform. We structure your submission to minimize avoidable RFIs by organizing evidence in the exact format URAC reviewers expect.
Phase 4: Desktop Review and RFI Response (Months 6-7)
A URAC Lead Reviewer scores each standard as Met or Not Met over a 30-to-45-day review window. You may receive up to two rounds of Requests for Information (RFIs) on gaps or ambiguities. IHS manages the RFI response process, rewriting policies and strengthening compliance evidence based on the specific reviewer concerns. Our experience with URAC reviewer expectations means our RFI responses address the root issue, not just the surface question.
Phase 5: Validation Review (Months 7-8)
URAC conducts an on-site, virtual, or hybrid validation review lasting 1 to 3 days. Reviewers interview staff, tour your facility, audit patient files, and review distribution logs. They are validating that your actual operations match the policies you documented. IHS prepares your team with mock interview sessions, facility walkthrough rehearsals, and patient file audits so every staff member demonstrates competence in the standards they are responsible for.
Phase 6: Committee Review and Decision (Months 8-9)
An anonymous, redacted version of your review report is submitted to the URAC Accreditation Committee, which votes twice monthly. Possible decisions: Full Accreditation, Conditional, Provisional, or Denied. Once accredited, the credential lasts 3 years with annual quality reporting requirements and random virtual monitoring reviews throughout the cycle.
Internal Staffing Requirements
Accreditation is not a consultant-only project. Your pharmacy needs dedicated internal resources throughout the process:
- Pharmacist-in-Charge (PIC): 1.0 FTE leading clinical policy adaptation and staff training
- Quality Assurance/Compliance Manager: 1.0 FTE for document control, software mapping, AccreditNet management, and RFI responses
- Total internal bandwidth: 1.5 to 3.0 FTEs during the 6-month preparation and application window, depending on facility size
External consultants cannot independently generate site-specific clinical data or conduct the internal staff training required for the Validation Review. IHS supplements your team's capacity — we do not replace it. Our model builds your staff's competence so you can maintain accreditation independently after the initial engagement.
What Does URAC Specialty Pharmacy Accreditation Cost?
URAC does not publish a flat-rate fee schedule. Accreditation fees are dynamically calculated based on your total annual pharmacy revenue, closely held company status, specific business model, and number of physical dispensing sites. The official URAC Specialty Pharmacy Accreditation Standards document costs $295. URAC's Small Business program offers special affordable pricing for eligible independent pharmacies under a revenue threshold.
Consulting fees vary by engagement scope. Comprehensive Standard-by-Standard Review and policy review typically runs $5,000 to $10,000. Targeted regulatory compliance assistance ranges from $3,000 to $9,000. Full-scope accreditation consulting projects span a wider range depending on pharmacy size and complexity. Hourly consulting rates range from $75 to $125 per hour for entry-level support, $150 to $250 per hour for experienced consultants, and $300+ per hour for highly specialized regulatory expertise. Post-accreditation monthly retainers for ongoing compliance support typically run $1,500 to $5,000 per month.
The critical cost consideration: URAC offers no refunds if accreditation is denied. Organizations that fail their survey lose their entire investment in application fees, preparation costs, and the months of internal staff time committed to the process. Consultant-led preparation is not an optional expense — it is risk mitigation against a non-refundable investment.
For a complete breakdown of fees, consulting costs, and internal resource requirements, see our URAC Specialty Pharmacy Accreditation Cost Guide.
Common URAC Specialty Pharmacy Accreditation Deficiencies and How to Avoid Them
The following deficiencies are the most frequent reasons specialty pharmacies receive RFIs, corrective action plans, or accreditation denials during their URAC survey. IHS has built prevention protocols for each one into our standard engagement workflow.
Primary Source Verification Failures (OPIN Module)
Verifications of clinical licensure and credentials are missing entirely, lack specific dates, or are not conducted at the frequency dictated by internal policy or URAC standards. IHS provides PSV tracking templates with audit-ready timestamp protocols and verification cadences from day one of the engagement.
Incomplete Clinical Assessments (PM Module)
Failure to consistently document required patient management clinical assessments within pharmacy management software at initiation of therapy. This is the single most flagged deficiency category across all specialty pharmacy surveys. IHS provides structured assessment templates and policy frameworks that align clinical documentation with URAC requirements — designed to integrate with your existing pharmacy management workflow.
Temperature and Cold-Chain Documentation Gaps (P-MD Module)
Inadequate distribution oversight — failing to conduct, maintain, or document temperature qualification testing and auditing, including cold-chain integrity for 36-hour shipping windows. With the expanding pipeline of complex biologics and cell/gene therapies, this standard is becoming more demanding in v6.0. IHS develops temperature qualification testing protocols and audit documentation frameworks that satisfy the standard.
Grievance Packet Deficiencies (CPE Module)
Failure to include mandatory state regulatory agency contact information in grievance and complaint packets provided to patients during onboarding. This is a straightforward compliance failure that is entirely preventable — IHS audits your patient-facing materials against every applicable state requirement.
Non-Individualized Care Plans (PM Module)
Utilizing identical boilerplate care plans across multiple patients rather than tailoring to the specific patient's comorbidities, disease state, or medication regimen. URAC reviewers compare patient files during validation reviews — duplicate care plans are immediately flagged. IHS develops care plan templates that require individualized clinical inputs while maintaining operational efficiency.
Incomplete Staff Competency Assessments (OPIN Module)
HR management of clinical and non-clinical staff competency assessments frequently incomplete, inconsistent, or poorly documented over time. IHS builds competency assessment schedules with documentation requirements for each role category in your pharmacy.
Performance Measure Reporting Failures (RPT Module)
Failures in tracking and submitting mandatory and exploratory performance measures to URAC on schedule. URAC-accredited specialty pharmacies achieved a 99.98% aggregate dispensing accuracy rate and a 2.73% average call abandonment rate (improved from 4.23% in the prior cycle) — your pharmacy needs to meet or approach these benchmarks. IHS provides performance measure tracking templates during the policy development phase.
Quality Committee Documentation Gaps (PMI Module)
Quality management program meeting minutes lacking actionable root cause analysis or follow-up documentation. IHS provides meeting minute templates that capture every element URAC reviewers look for, including specific follow-up items with assigned accountability and deadlines.
Documentation Organization Gaps
Manual mapping of standards to documentation systems using disjointed spreadsheets rather than organized compliance frameworks. IHS provides documentation templates and organizational structures that align with URAC reviewer expectations, reducing the risk of disjointed evidence submissions.
Why Choose IHS for URAC Specialty Pharmacy Accreditation Consulting
IHS is a specialized healthcare accreditation consulting firm with over 25 years of URAC and NCQA expertise. Here is what that means for your specialty pharmacy accreditation engagement.
- Deep standards expertise: Over 25 years guiding organizations through URAC Specialty Pharmacy Accreditation. We know these standards at the element level because we work with them every day — across every version from the original through v5.0.
- v5.0-to-v6.0 transition expertise: IHS has the strongest plain-language change-summary content in the specialty pharmacy accreditation market. We translate standards updates into actionable operational guidance, not regulatory jargon.
- PM module compliance specialization: The Patient Management module is the most commonly flagged deficiency category. No external source provides actionable compliance guidance for PM module requirements. IHS does.
- Policy templates and compliance frameworks: We provide Patient Management policy templates and clinical assessment frameworks designed to integrate with your pharmacy operations. Your team documents compliance during normal workflow, not as a separate administrative burden.
- Hospital outpatient pharmacy / 340B pathway: No competitor specifically addresses the distinct requirements hospital outpatient pharmacies face during URAC accreditation. IHS has built this pathway.
- Dual URAC + ACHC strategy: For pharmacies that need both accreditations to maximize payer network access and limited distribution drug eligibility, IHS advises on sequencing, cost optimization, and documentation reuse across both programs.
- Cost transparency: We publish consulting fee ranges and explain URAC's dynamic fee structure. Every other firm says "contact us."
- Principal-led engagement: Thomas G. Goddard, JD, PhD, leads every IHS engagement. You work directly with the firm's principal, not a junior associate.
If you are evaluating URAC versus ACHC for your specialty pharmacy, see our URAC vs ACHC Specialty Pharmacy Accreditation comparison.
Frequently Asked Questions
What is URAC specialty pharmacy accreditation?
URAC Specialty Pharmacy Accreditation is a three-year quality credential from the Utilization Review Accreditation Commission recognizing specialty pharmacies that meet rigorous standards across 9 operational modules. The current standard is v6.0, announced October 2025. Approximately 465 URAC-accredited organizations reported measurement year data in 2024, and roughly 1,900 total dispensing locations hold specialty pharmacy accreditation across all credentialing bodies nationally.
Which PBMs require URAC specialty pharmacy accreditation?
OptumRx contractually requires URAC, ACHC, or TJC accreditation for specialty pharmacy network participation. CVS Caremark and Express Scripts maintain similar credentialing requirements. Approximately 66% of commercial payers prefer URAC accreditation specifically.
How long does URAC specialty pharmacy accreditation take?
9 to 12 months from consulting engagement kickoff to committee decision. URAC advertises 6 months from application submission, but this assumes existing operational readiness. The timeline spans Standard-by-Standard Review, policy development, application, desktop review, validation review, and committee decision.
How much does URAC specialty pharmacy accreditation cost?
URAC fees are dynamically calculated based on pharmacy revenue, business model, and number of dispensing sites. The standards document costs $295. Consulting engagements for Standard-by-Standard Review run $5,000 to $10,000. See our cost guide for a complete breakdown.
What is the difference between URAC and ACHC specialty pharmacy accreditation?
URAC is preferred by approximately 66% of commercial payers and emphasizes clinical patient management and operational quality metrics. ACHC focuses on pharmacy operations and has strategic partnerships with independent pharmacy compliance firms. Many pharmacies pursue dual accreditation for maximum network access. See our full comparison.
Can a hospital outpatient pharmacy get URAC specialty pharmacy accreditation?
Yes. Hospital and health system outpatient pharmacies are the fastest-growing segment, expanding from 15% to 27% of accredited specialty pharmacies between 2017 and 2024. Many pursue URAC accreditation to maximize 340B Drug Pricing Program benefits.
What are the most common URAC specialty pharmacy survey deficiencies?
Top deficiencies include Primary Source Verification failures (OPIN module), incomplete Patient Management clinical assessments (PM module), temperature and cold-chain documentation gaps (P-MD module), missing state regulatory information in grievance packets (CPE module), non-individualized care plans, incomplete staff competency assessments, and performance measure reporting failures.
What does a URAC specialty pharmacy accreditation consultant do?
A URAC specialty pharmacy consultant conducts Standard-by-Standard Review against v6.0 standards across all 9 modules, develops compliance documentation, provides PM policy templates and compliance frameworks, manages AccreditNet submissions, conducts mock desktop reviews, and handles RFI responses. IHS provides end-to-end support from initial assessment through final accreditation.
Is there a URAC program for small specialty pharmacies?
Yes. URAC offers a dedicated Small Business Specialty Pharmacy Accreditation program with special affordable pricing for eligible independent, community, and private pharmacies under a revenue threshold. Self-reporting of metrics is available for qualifying small businesses.
Does North Carolina law protect URAC-accredited pharmacies?
Yes. North Carolina Session Law 2025-69 provides explicit statutory protection for URAC-accredited pharmacies against PBM-imposed redundant credentialing documentation requirements exceeding NC Board of Pharmacy standards. URAC accreditation serves as a legal shield against arbitrary PBM credentialing demands in that state.
Ready to Get Started?
Schedule a no-obligation Standard-by-Standard Review with IHS. We will assess your current compliance posture against URAC Specialty Pharmacy v6.0 standards and give you a clear roadmap to accreditation.